Random chart - brand drug hopping

 

The Cost of Brand Drug Product Hopping (8-page PDF) 

Random charts - medical marketing

Source: Medical Marketing in the United States, 1997-2016 (JAMA)

Random charts - Medicare & PBMs

Source: MEDICARE PART D: Use of Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures and Utilization (78-pg GAO PDF)

 

"What GAO Found: Medicare Part D plan sponsors used pharmacy benefit managers (PBM) to provide 74 percent of drug benefit management services and performed the remaining 26 percent of services themselves in 2016—the most recent year of data at the time of our analysis. Plan sponsors are private entities that operate drug plans; PBMs are organizations that help manage drug benefits. Rebates and other price concessions—discounts generally paid by manufacturers to Part D plan sponsors and PBMs after the sale of a drug at the pharmacy—grew faster than Part D expenditures from 2014 through 2016. Specifically, gross expenditures (the amount paid to pharmacies by plan sponsors, or by the PBM on the sponsor’s behalf, and by the beneficiary) increased 20 percent, to $145.1 billion. During this period, rebates and other price concessions increased 66 percent, to $29 billion—20 percent of 2016 gross expenditures. Consequently, net expenditures (gross expenditures less rebates and other price concessions) increased only 13 percent, to $116.1 billion..."

Random charts - hospital pharmacy

Source: ASHP national survey of pharmacy practice in hospital settings: Workforce—2018

Random chart - drug discovery

Source: Academia and industry: allocating credit for discovery and development of new therapies

Random chart - drug spend

Source: How Does Prescription Drug Spending and Use Compare Across Large Employer Plans, Medicare Part D, and Medicaid?

Random chart - P-A DO

Source: U.S. Distribution and Reimbursement System: Patient- Administered Outpatient Drugs

Random charts - FDA

Source: The FDA’s Drug Pricing Strategy: What’s New?

"...To help track the FDA’s progress in implementing its strategy, we’ve created a timeline of the major announcements and regulatory actions the agency has taken to encourage a competitive market for biologic drugs, address drug shortages and abuses of the FDA’s citizen petition process, and streamline the Risk Evaluation and Mitigation Strategies (REMS) program, which aims to promote timelier competition from generic drug manufacturers. We’ll be updating this periodically. In a future post, we’ll discuss additional steps the agency and Congress could take to lower drug prices..."

Random charts - medicines

Source: The Global Use of Medicine in 2019 and Outlook to 2023: Forecasts and Areas to Watch (reg.reqd.)

Random charts - orphan drugs

Source: Orphan Drugs in the United States: Exclusivity, Pricing and Treated Populations (23-pg PDF, registration reqd.)

Random charts - antibiotics

 

 

Source: WHO Report on Surveillance of Antibiotic Consumption  (115-pg PDF)

"Antimicrobial resistance is a major threat to health and human development, affecting our ability to treat a range of infections. Treatments for a growing number of infections have become less effective in many parts of the world due to resistance. The link between antimicrobial resistance and use of antimicrobials is well documented. However, little information is available on antimicrobial use in low-income countries. This report presents 2015 data on the consumption of systemic antibiotics from 65 countries and areas, contributing to our understanding of how antibiotics are used in these countries. In addition, the report documents early efforts of the World Health Organization (WHO) and participating countries to monitor antimicrobial consumption, describes the WHO global methodology for data collection, and highlights the challenges and future steps in monitoring antimicrobial consumption."

Random chart - generic profits

Source: Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion

"... Teva Pharmaceutical Industries Ltd. plummeted the most in six months after U.S. sales fell amid price erosion for generic drugs, the company’s biggest business. The 18 percent slump in overall second-quarter sales to $4.7 billion trailed analysts’ average estimate and was led by a decline in sales of copycat drugs in North America. Rapid approvals for generic medicines and consolidation of big pharma buyers continued to squeeze industry profitability for a second year..."

Random charts - drug prices

 

Source: Drug Price Forecast Highlights: July-August 2018

Random charts - drug prices

 

 

 

Source: The FDA is approving more generic drugs than ever before, faster than ever before. Is it enough to lower drug costs? (10-pg pwc PDF)

Random chart - drug prices

Source: Why Retail Pharmacies Still Overcharge Uninsured Patients—And What That Means for Amazon

Random charts - drug pricing

Source: Reforming Biopharmaceutical Pricing at Home and Abroad (28-page CEA PDF)

Random charts - drug industry

Source: Drug Industry: Profits, Research and Development Spending, and Merger and Acquisition Deals (73-pg GAO PDF)

Random chart - profitability

Source: Health care profits concentrated at drug companies

"Ninety-nine of the largest publicly traded health care companies cumulatively collected $33 billion of profit and $577 billion of revenue worldwide in the third quarter this year, according to earnings reports we tracked. Pharmaceutical companies collected more than 60% of those profits, but only 22% of the revenu."

Random charts - 340(B)

Source: A $1.6B cut to 340B payments, plus outpatient TKA: Our key takeaways on the 2018 Outpatient Final Rule